Verona Pharma PLC Directorate Change

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
                              Directorate Change 
 
11 January 2016, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
announces the resignation of Biresh Roy, Chief Financial Officer of the 
Company. He will step down from the Board with immediate effect but will remain 
with Verona Pharma for up to six months to allow time for a suitable successor 
to be appointed and for an orderly handover. The Board has commenced a search 
for his successor and a further announcement will be made in due course. 
 
Dr. David Ebsworth, Chairman of Verona Pharma, said: "The Board would like to 
thank Biresh for his many contributions to the Company. This has been a 
particularly formative time for Verona Pharma as it has delivered on important 
operational and clinical goals it set at the time of the 2014 Financing in a 
timely manner. Importantly, Biresh's financial stewardship has also ensured 
that these goals have been met on, or ahead of, budget. We warmly wish Biresh 
all the best in his future endeavours." 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                      Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive 
Officer 
 
N+1 Singer                             Tel: +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                         Tel: +44 (0)20 3727 1000 
Simon Conway / Stephanie Cuthbert / 
Natalie Garland-Collins 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
II trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting.  The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value.  This includes the 
very significant markets for COPD and asthma maintenance therapy.  The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has received a Venture 
and Innovation Award from the Cystic Fibrosis Trust. 
 
 
 
END

(END) Dow Jones Newswires

January 11, 2016 02:00 ET (07:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024